Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976958 | 0.94 | MAPT (0.50) | MAPTTP53HSP90AB1LMNAPOLB | |
| SCHEMBL4980399 | 0.89 | MAPT (0.75) | MAPTTP53HSP90AB1LMNAPOLB | |
| SCHEMBL4981551 | 0.82 | HSP90AB1 (0.61) | MAPTTP53HSP90AB1LMNAPOLB | |
| SCHEMBL4979044 | 0.82 | MAPT (0.64) | MAPTTP53HSP90AB1LMNAPOLB | |
| SCHEMBL4973632 | 0.81 | MAPT (0.60) | MAPTTP53HSP90AB1LMNAPOLB | |
| SCHEMBL4975134 | 0.81 | LMNA (0.76) | MAPTTP53HSP90AB1LMNAPOLB | |
| SCHEMBL4979825 | 0.81 | HSP90AB1 (0.73) | MAPTTP53HSP90AB1LMNAPOLB | |
| SCHEMBL4980630 | 0.80 | HSP90AB1 (0.66) | MAPTTP53HSP90AB1LMNA | |
| SCHEMBL4976666 | 0.80 | ERCC1 (0.46) | HSP90AB1 | |
| SCHEMBL4974739 | 0.80 | LMNA (0.60) | MAPTTP53HSP90AB1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | MAPT 2301/4885TP53 1765/4885HSP90AB1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.